Results of clinical trial involving Brentuximab Vedotin with autologous stem cell transplant as second line therapy for Hodgkin lymphoma.
Home / Resource Library / Autologous Stem Cell Transplantation After Second Line Brentuximab Vedotin in Relapsed or Refractory Hodgkin Lymphoma